FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer
The FDA approved Novartis’ Pluvicto (lutetium Lu-177 vipivotide tetraxetan) for PSMA-positive metastatic hormone-sensitive prostate cancer, to be used with an androgen receptor pathway inhibitor and androgen deprivation therapy. Based on the PSMAddition phase 3 trial, radiographic PFS improved (HR 0.72). OS data are immature, and grade 3+ adverse events were higher (50.7% vs 43%).
How this was made
The 30-second read
Why it matters
The FDA’s approval expands Pluvicto into the metastatic hormone-sensitive setting in combination with ARPI and ADT, supported by improved radiographic PFS and a favorable but immature OS trend.
Market read
Regulatory label expansion is a concrete, time-sensitive catalyst for the sponsor’s oncology franchise and can reprice expectations for earlier-line treatment penetration.
What to watch
Commercial impact will hinge on combination prescribing patterns with ARPI and ADT, reimbursement coverage for earlier-line use, and operational capacity for Lu-177 supply and administration.
Background
Pluvicto was previously approved for PSMA-positive metastatic castration-resistant prostate cancer after prior ARPI therapy and chemotherapy, with later expansion to pre-chemotherapy use.
Ticker impact
FDA expanded Pluvicto (lutetium Lu-177 vipivotide tetraxetan) approval to PSMA-positive metastatic hormone-sensitive prostate cancer with ARPI and ADT, based on PSMAddition trial results.
Likely positive near-term sentiment for NVS on expanded commercialization runway, with follow-through dependent on uptake and payer/clinical adoption.
The article is a direct FDA approval expansion tied to phase 3 efficacy (radiographic PFS HR 0.72) and safety (higher grade 3+ AEs), which is typically material for oncology product revenue expectations.
Market effects
Reinforces radioligand therapy momentum in earlier-stage metastatic prostate cancer and may increase competitive pressure for PSMA-targeted and ARPI sequencing strategies.
US regulatory action can accelerate global adoption timelines and formulary discussions for multinational oncology portfolios.
Earlier-line approval can shift treatment standards internationally, affecting demand forecasts for PSMA radioligand supply and partner ecosystems.
Counterpoint
OS benefit is immature and grade 3+ adverse events are higher, so real-world uptake could be slower than the headline suggests.
Key entities
- drugPluvicto (lutetium Lu-177 vipivotide tetraxetan)
Radioligand therapy whose FDA label is expanded to PSMA-positive metastatic hormone-sensitive prostate cancer with ARPI and ADT.
- clinical_trialPSMAddition trial
Phase 3 randomized study comparing Pluvicto plus standard of care versus standard of care alone, showing improved radiographic PFS.
- personMichael J. Morris, MD
Principal investigator of PSMAddition and quoted in the sponsor’s press release.
